Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme (Q43989660)

28 November 2017

title

Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme (English)

1 reference

28 November 2017

1 reference

5

1 reference

28 November 2017

Aida Muhic

1

1 reference

28 November 2017

Hans Skovgaard Poulsen

series ordinal

2

1 reference

28 November 2017

Morten Sorensen

series ordinal

3

1 reference

28 November 2017

Kirsten Grunnet

series ordinal

4

1 reference

28 November 2017

publication date

27 November 2012

1 reference

Journal of Neuro-Oncology

28 November 2017

published in

1 reference

28 November 2017

volume

111

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

205-212

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

PIK3CA alterations in primary (de novo) and secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Response assessment in neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

The angiogenic switch in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Brain distribution of cediranib is limited by active efflux at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Angiogenesis as a therapeutic target in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme--improvement over available therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Pathway inhibition: emerging molecular targets for treating glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1009-Y

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

12 December 2020

Current data and strategy in glioblastoma multiforme

1 reference

12 December 2020

3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family

1 reference

12 December 2020

Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme

1 reference

12 December 2020

Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model

1 reference

12 December 2020

Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients.

1 reference

12 December 2020

10.1007/S11060-012-1009-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

28 November 2017

1046618479

0 references

Fatcat ID

release_a5ekcct7crawvpbhhd727vmfyy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a5ekcct7crawvpbhhd727vmfyy

24 November 2022

mapped directly with Wikidata item

1 reference